Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 5/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7899060 | 1.00 | TRPV6 (0.58) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| SCHEMBL22834418 | 1.00 | TRPV6 (0.58) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| SCHEMBL4797625 | 0.92 | SIGMAR1 (0.69) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| SCHEMBL2085351 | 0.87 | NPC1 (0.61) | SIGMAR1RECQLSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL3709310 | 0.86 | RECQL (0.70) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL3706762 | 0.85 | RECQL (0.68) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| SCHEMBL13943667 | 0.85 | SIGMAR1 (0.64) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| SCHEMBL1204089 | 0.84 | TRPV6 (0.58) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| SCHEMBL18177889 | 0.84 | ACHE (0.70) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| SCHEMBL2336883 | 0.83 | KDM4E (0.65) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564591-B2 | HCK as a therapeutic target in MYD88 mutated diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4041239-B1 | A PYRRAZOLOPYRIMIDINE DERIVATIVE AS A HCK INHIBITOR FOR USE IN THERAPY, IN PARTICULAR MYD88 MUTATED DISEASES | DANA FARBER CANCER INST INC (US) | 2025-09-03 | — | — | EP | disclosed |
| CN-114746095-B | HCK as therapeutic target of MYD88 mutant diseases | 达纳-法伯癌症研究所有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-118201929-A | PROTAC compound, pharmaceutical composition containing same, and preparation method and application thereof | 广东弘烨医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023072270-A1 | PROTAC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 百极弘烨(南通)医药科技有限公司 | 2023-05-04 | — | — | WO | disclosed |
| US-20220395509-A1 | A PYRAZOLOPYRIMIDINE DERIVATIVE AS A HCK INHIBITOR FOR USE IN THERAPY, IN PARTICULAR MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220372017-A1 | HCK DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| EP-4041239-A1 | A PYRAZOLOPYRIMIDINE DERIVATIVE AS A HCK INHIBITOR FOR USE IN THERAPY, IN PARTICULAR MYD88 MUTATED DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114746095-A | HCK as therapeutic target of MYD88 mutant disease | 达纳-法伯癌症研究所有限公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3986397-A1 | HCK DEGRADERS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-9212190-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2802330-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013106535-A9 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20130231328-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2013106535-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| EP-1023273-B1 | CYCLOHEXANE DERIVATIVES DIFUNCTIONALISED IN 1,4 AS LIGANDS OF 5HT1A RECEPTORS | PF MEDICAMENT (FR) | 2002-06-05 | — | — | EP | disclosed |
| US-6191130-B1 | HYPOTENSIVE AGENTS; THERAPY FOR SEXUAL DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2001-02-20 | — | — | US | disclosed |
| EP-1023273-A1 | CYCLOHEXANE DERIVATIVES DIFUNCTIONALISED IN 1,4 AS LIGANDS OF 5T H1A RECEPTORS | PIERRE FABRE MEDICAMENT (FR) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999020613-A1 | CYCLOHEXANE DERIVATIVES DIFUNCTIONALISED IN 1,4 AS LIGANDS OF 5T H1A RECEPTORS | PIERRE FABRE MEDICAMENT (FR) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372017-A1 | HCK DEGRADERS AND USES THEREOF | CRBN, HCK, CRKL | TRPV6 4670/4885SIGMAR1 3543/4885RECQL 1186/4885 |
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TRPV6 3919/4885SIGMAR1 3795/4885RECQL 2685/4885 |
| US-20220395509-A1 | A PYRAZOLOPYRIMIDINE DERIVATIVE AS A HCK INHIBITOR FOR USE IN THERAPY, IN PARTICULAR MYD88 MUTATED DISEASES | HCK, BTK, MYD88 | TRPV6 4248/4885SIGMAR1 2257/4885RECQL 1823/4885 |
| US-12564591-B2 | HCK as a therapeutic target in MYD88 mutated diseases | HCK, BTK, LYN | TRPV6 4103/4885SIGMAR1 1819/4885RECQL 2674/4885 |
| US-20130231328-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TRPV6 3919/4885SIGMAR1 3795/4885RECQL 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.